Ceftaroline Will Earn Peak Year Sales of up to $200 Million in the Community-Acquired Pneumonia Drug Market

Tuesday, March 2, 2010 General News
Email Print This Page Comment bookmark
Font : A-A+

Between 2010 and 2015, Ceftaroline is Poised to be the Only Marketed Anti-MRSA Cephalosporin for the Indication, According to New Findings from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

[email protected]



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook